EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effect of a Single Oral Dose of Dexamphetamine or Zolpidem on Attention and Reaction Time in Healthy Men

Veronika Pfoser-Poschacher iD, Michael Wolf, Michaela Bayerle-Eder, Teresa Wimmer, Daniela Boryshchuk, Christopher Gerner, Michael Wolzt

Fundamental & Clinical Pharmacology · 2026-05 · 40 (3)

DOI: 10.1111/fcp.70092 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 05.05.2026. Verfasst von Veronika Pfoser-Poschacher und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Attention, Dextroamphetamine, Reaction Time, Zolpidem. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Clinical Pharmacology, Medical University of Vienna, Austria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychotropic medicines are known to impair cognitive function acutely, but the specific effects of individual substances remain underexplored. This study investigates the effects of dexamphetamine and zolpidem on cognitive performance to quantify the potential risk of intake and their pharmacokinetic and pharmacodynamic relationship. This randomized, double‐blind, placebo‐controlled trial (EudraCT 2021–005381 − 17) included 60 healthy men aged 26 ± 5 (mean ± SD) years. Participants received a single oral dose of 30‐mg dexamphetamine, 5‐mg zolpidem, or placebo ( n = 20 per group). Cognitive performance was assessed at baseline and 3 and 8 h after dosing using the computerized Psytest system. Dexamphetamine and zolpidem improved sustained attention, with significant reduction of omissions at 8 h. Reaction time improved in both groups, but zolpidem impaired phasic alertness. Working memory remained unchanged. Plasma concentration of dexamphetamine and zolpidem was 70.8 ± 10.4 ng/mL and 39.0 ± 20.7 ng/mL at 3 h and 45.9 ± 7.9 ng/mL and 8.7 ± 6.6 ng/mL at 8 h, respectively. No correlation between drug plasma concentration and cognitive performance measures was demonstrable. Dexamphetamine caused the strongest subjective effects and highest liking ratings, whereas zolpidem elicited greater subjective dislike. Tolerability was best with placebo, followed by zolpidem and dexamphetamine. Single therapeutic doses of dexamphetamine and zolpidem modestly affected cognitive function 3 h after intake, with no relationship between cognitive performance and the study medicines' plasma concentration. Both medicines improve cognition after 8 h but differed in subjective emotional effects. Nevertheless, generalizability is limited by the inclusion of healthy men only. Trial Registration: EudraCT: Nr: 2021–005381‐17

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AttentionDextroamphetamineReaction TimeZolpidemCentral Nervous System StimulantsAdultHumansMaleYoung AdultAdministration, OralCognitionCognitive EnhancementDouble-Blind MethodHealthy Volunteers

Stichwörter der Autor:innen

Psytestalertnessdexamphetaminepharmacokineticreaction timezolpidem

Substanzen

DextroamphetamineZolpidemCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Department of Physical Medicine and Rehabilitation, Herz Jesu Hospital, Vienna, Austria.
  • Department of Analytical Chemistry, University of Vienna, Vienna, Austria.
  • Department of Clinical Pharmacology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Veronika Pfoser-Poschacher

Förderung

  • Department of Clinical Pharmacology, Medical University of Vienna, Austria

Zitieren

APA

Pfoser-Poschacher, V., Wolf, M., Bayerle-Eder, M., Wimmer, T., Boryshchuk, D., Gerner, C., & Wolzt, M. (2026). Effect of a Single Oral Dose of Dexamphetamine or Zolpidem on Attention and Reaction Time in Healthy Men. Fundamental & Clinical Pharmacology, 40(3). https://doi.org/10.1111/fcp.70092

Vancouver

Pfoser-Poschacher V, Wolf M, Bayerle-Eder M, Wimmer T, Boryshchuk D, Gerner C, et al. Effect of a Single Oral Dose of Dexamphetamine or Zolpidem on Attention and Reaction Time in Healthy Men. Fundamental & Clinical Pharmacology. 2026;40(3). doi:10.1111/fcp.70092

BibTeX
@article{PfoserPoschacher2026,
  author = {Pfoser-Poschacher, Veronika and Wolf, Michael and Bayerle-Eder, Michaela and Wimmer, Teresa and Boryshchuk, Daniela and Gerner, Christopher and Wolzt, Michael},
  title = {Effect of a Single Oral Dose of Dexamphetamine or Zolpidem on Attention and Reaction Time in Healthy Men},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2026},
  volume = {40},
  number = {3},
  doi = {10.1111/fcp.70092}
}
Kostenlos starten →